Publications

Mouse peritonitis/sepsis model

Title, authors, reference

09/2012

50% Effective dose (ED50) Determination of KPI-10 for Treating Sepsis in Mice Due to Fluoroquinolone-Susceptible (FQ-S) and Fluoroquinolone-Resistant (FQ-R) Nosocomial Pathogens: Comparison with Ciprofloxacin (CIP). C. Jacqueline, M. Davieau, C. Desessard, A.F. Miègeville, Y. Ge, G. Potel, J. Caillon. ICAAC 2012. Poster n° F-2056.


09/2010

ED50 Determination of CXA-101 Alone and in Combination with Tazobactam (TAZ) for Treating Experimental Peritonitis in Mice Due to ESBL-Producing Klebsiella pneumonia (KP) Strains: Comparison with Ceftazidime (CAZ) and Piperacillin/Tazobactam (TZP). C. Jacqueline,  C. Desessard, G. Amador, E. Batard, A. F. Miegeville,  J. Y. Ge, G. Potel , J. Caillon. ICAAC 2010. Poster n° B-708.


02/2005

Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy. Asseray N, Jacqueline C, Le Mabecque V, Batard E, Bugnon D, Potel G, Caillon J. Antimicrob Agents Chemother. 2005 Feb; 49 (2): 857-9.


01/2005

Influence of carbon dioxide on the MIC of telithromycin for Streptococcus pneumoniae: an in vitro-in vivo study. Batard E, Juvin ME, Jacqueline C, Bugnon D, Caillon J, Potel G, Drugeon HB. Antimicrob Agents Chemother. 2005 Jan; 49 (1): 464-6